title: Ultrafiltration of the priming blood before cardiopulmonary bypass attenuates inflammatory response and improves postoperative clinical course in pediatric patients.
abstract: The priming solution using in cardiopulmonary bypass (CPB) for infants undergoing cardiac surgery includes considerable amounts of stored blood. Our objective was to test the hypothesis that ultrafiltration (UF) of the stored blood before CPB reduces the unfavorable effects of stored blood and the production of inflammatory cytokines. Fifty pediatric patients with congenital heart defects took part in this study. The patients were randomly divided into two groups: the UF (27 pediatric patients who received UF) and control (23 pediatric patients who did not receive UF) groups. UF was performed with a polysulphone ultrafiltrator before CPB. Blood samples were collected immediately before, during, and 1 h after CPB. The levels of cytokines (TNF-alpha, IL-1beta, IL-8), NH3, and bradykinin were determined. The serum concentrations of NH3 and bradykinin decreased significantly after UF. Compared with the control group, the UF group had significantly lower cytokine production. Water balance in UF group was better than that of control group. The UF group received significantly less inotropic support and shorter duration of ventilator support and ICU stay. We conclude that removal of bradykinin and a decrease in the levels of NH3, potassium, and pH play a significant role in reducing water retention and postoperative lung injury. UF of the blood used to prime the circuit for CPB is a safe and efficient method for use in open heart surgery in small pediatric patients.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Hokkaido University School of Medicine, Mie University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Shimpo
authors.forename: A
authors.initials: A
authors.lastname: Shimamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Sawamura
authors.forename: K
authors.initials: K
authors.lastname: Fujinaga
authors.forename: S
authors.initials: S
authors.lastname: Kanemitsu
authors.forename: K
authors.initials: K
authors.lastname: Onoda
authors.forename: M
authors.initials: M
authors.lastname: Takao
authors.forename: Y
authors.initials: Y
authors.lastname: Mitani
authors.forename: I
authors.initials: I
authors.lastname: Yada
mesh_terms: D000641:Ammonia / Q000097:blood; D001920:Bradykinin / Q000097:blood; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods*; D016207:Cytokines / Q000097:blood; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D007249:Inflammation / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D011183:Postoperative Complications / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D011188:Potassium / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014462:Ultrafiltration / Q000379:methods*; D014882:Water-Electrolyte Balance
chemical_list: D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D000641:Ammonia; D011188:Potassium; D001920:Bradykinin